Details of the Drug

General Information of Drug (ID: DMPNUYZ)

• Drug Name: Autologous VEGF-and angiopoietin-1-expressing endothelial and smooth muscle cell therapy
• Synonyms: MultiGeneAngio; Autologous VEGF-and angiopoietin-1-expressing endothelial and smooth muscle cell therapy (cardiovascular disease); VEGF-114 based therapy (cardiovascular disease), Compugen/MGVS; VEGF-114 based therapy (cardiovascular disease), Compugen/MultiGene Vascular Systems; Autologous VEGF-and angiopoietin-1-expressing endothelial and smooth muscle cell therapy (cardiovascular disease), Compugen/MGVS; Autologous VEGF-and angiopoietin-1-expressing endothelial and smooth muscle cell therapy (cardiovascular disease), Compugen/MultiGene Vascular Systems

Indication

Disease Entry	ICD 11	Status	REF
Cardiovascular disease	BA00-BE2Z	Phase 1/2	[1]
Peripheral arterial disease	BD4Z	Phase 1/2	[2]

• Cross-matching ID: TTD ID: D05TWD
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

References

• [1] ClinicalTrials.gov (NCT00390767) Safety Study of MultiGeneAngio in Patients With Peripheral Arterial Disease (PAD). U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)